146 related articles for article (PubMed ID: 9612707)
1. Cost analysis of treatments for severe combined immunodeficiency patients caused by adenosine deaminase deficiency: comparison of gene therapy and bone marrow transplantation.
Imai H
Hokkaido Igaku Zasshi; 1998 Mar; 73(2):137-45. PubMed ID: 9612707
[TBL] [Abstract][Full Text] [Related]
2. Management options: SCIDS with adenosine deaminase deficiency.
Hilman BC; Sorensen RU
Ann Allergy; 1994 May; 72(5):395-403; quiz 403-4, 407. PubMed ID: 8179225
[TBL] [Abstract][Full Text] [Related]
3. [Adenosine deaminase deficiency].
Sakiyama Y
Ryoikibetsu Shokogun Shirizu; 2000; (32):32-4. PubMed ID: 11212730
[No Abstract] [Full Text] [Related]
4. [It is no more about cancer, but it is already about gene therapy].
Jeanteur P
Bull Cancer; 2000 Jun; 87(6):445-6. PubMed ID: 10928794
[No Abstract] [Full Text] [Related]
5. [Cost of leukemia treatment].
Masaoka T; Hiraoka A
Gan To Kagaku Ryoho; 1991 Jul; 18(9):1415-20. PubMed ID: 1854212
[TBL] [Abstract][Full Text] [Related]
6. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.
Hershfield MS
Semin Hematol; 1998 Oct; 35(4):291-8. PubMed ID: 9801258
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of severe combined immunodeficiency with bone marrow or foetal liver transplants (author's transl)].
Touraine JL
Nouv Presse Med; 1980 Sep; 9(32):2215-9. PubMed ID: 6999458
[TBL] [Abstract][Full Text] [Related]
8. Hyperbilirubinemia and rapid fatal hepatic failure in severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA-SCID).
Kühl JS; Schwarz K; Münch A; Schmugge M; Pekrun A; Meisel C; Wahn V; Ebell W; von Bernuth H
Klin Padiatr; 2011 Mar; 223(2):85-9. PubMed ID: 21271505
[TBL] [Abstract][Full Text] [Related]
9. PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency.
Hershfield MS
Hum Mutat; 1995; 5(2):107-12. PubMed ID: 7749407
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for severe combined immune deficiency.
Qasim W; Gaspar HB; Thrasher AJ
Expert Rev Mol Med; 2004 Jul; 6(13):1-15. PubMed ID: 15236670
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency by autologous transplantation of genetically modified bone marrow cells.
Hoogerbrugge PM; Vossen JM; v Beusechem VW; Valerio D
Hum Gene Ther; 1992 Oct; 3(5):553-8. PubMed ID: 1420454
[No Abstract] [Full Text] [Related]
12. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia.
van Agthoven M; Groot MT; Verdonck LF; Löwenberg B; Schattenberg AV; Oudshoorn M; Hagenbeek A; Cornelissen JJ; Uyl-de Groot CA; Willemze R
Bone Marrow Transplant; 2002 Aug; 30(4):243-51. PubMed ID: 12203141
[TBL] [Abstract][Full Text] [Related]
13. Bilateral sensorineural deafness in adenosine deaminase-deficient severe combined immunodeficiency.
Albuquerque W; Gaspar HB
J Pediatr; 2004 Feb; 144(2):278-80. PubMed ID: 14760277
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb.
Patel NC; Chinen J; Rosenblatt HM; Hanson IC; Brown BS; Paul ME; Abramson SL; Ritz J; Shearer WT
J Allergy Clin Immunol; 2008 Dec; 122(6):1185-93. PubMed ID: 19084111
[TBL] [Abstract][Full Text] [Related]
15. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
[TBL] [Abstract][Full Text] [Related]
16. Neonatal screening for severe combined immunodeficiency caused by an adenosine deaminase defect: a reliable and inexpensive method using tandem mass spectrometry.
Azzari C; la Marca G; Resti M
J Allergy Clin Immunol; 2011 Jun; 127(6):1394-9. PubMed ID: 21624616
[TBL] [Abstract][Full Text] [Related]
17. [Cost analysis of the treatment of Hodgkin's disease].
Charlińiski G; Wiktor-Jedrzejczak W
Wiad Lek; 2006; 59(3-4):164-9. PubMed ID: 16813258
[TBL] [Abstract][Full Text] [Related]
18. Primary immunodeficiencies: molecular aspects and treatment.
Fischer A
Bone Marrow Transplant; 1992; 9 Suppl 1():39-43. PubMed ID: 1354525
[No Abstract] [Full Text] [Related]
19. Costing of severe pneumonia in hospitalized infants and children aged 2-36 months, at a secondary and tertiary level hospital of a not-for-profit organization.
Madsen HO; Hanehøj M; Das AR; Moses PD; Rose W; Puliyel M; Konradsen F; John KR; Bose A
Trop Med Int Health; 2009 Oct; 14(10):1315-22. PubMed ID: 19719464
[TBL] [Abstract][Full Text] [Related]
20. A review of the costs, cost-effectiveness and third-party charges of bone marrow transplantation.
Westerman IL; Bennett CL
Stem Cells; 1996 May; 14(3):312-9. PubMed ID: 8724697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
